Stoke Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Stoke Therapeutics, Inc. (STOK) reported Other Comprehensive Income (Loss), Net of Tax of -$427.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-03
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$427.00K, a 313.50% decline year-over-year.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$658.00K, a 1500.00% decline year-over-year.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $97.00K.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $350.00K, a 93.37% increase year-over-year.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $694.00K.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$127.00K, a 111.03% decline from fiscal 2023.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $1.15M.
- Stoke Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$1.01M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$427.00K 10-Q · filed 2026-08-03 | -$1.08M 10-Q · filed 2026-08-03 | -$988.00K derived: sum of 3 quarters · filed 2026-08-03 | -$638.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$658.00K 10-Q · filed 2026-05-07 | -$561.00K derived: sum of 2 quarters · filed 2026-05-07 | -$211.00K derived: sum of 3 quarters · filed 2026-05-07 | -$11.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $447.00K derived: sum of 2 quarters · filed 2026-03-16 | $647.00K derived: sum of 3 quarters · filed 2026-08-03 | $694.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $350.00K 10-Q · filed 2025-11-04 | $550.00K derived: sum of 2 quarters · filed 2026-08-03 | $597.00K 10-Q · filed 2025-11-04 | $280.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-03 | $247.00K 10-Q · filed 2026-08-03 | -$70.00K derived: sum of 3 quarters · filed 2026-08-03 | $111.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $47.00K 10-Q · filed 2026-05-07 | -$270.00K derived: sum of 2 quarters · filed 2026-05-07 | -$89.00K derived: sum of 3 quarters · filed 2026-05-07 | -$104.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$136.00K derived: sum of 2 quarters · filed 2026-03-16 | -$151.00K derived: sum of 3 quarters · filed 2026-03-16 | -$127.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $181.00K 10-Q · filed 2025-11-04 | $166.00K derived: sum of 2 quarters · filed 2025-11-04 | $190.00K 10-Q · filed 2025-11-04 | $313.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$15.00K 10-Q · filed 2025-08-12 | $9.00K 10-Q · filed 2025-08-12 | $132.00K derived: sum of 3 quarters · filed 2025-08-12 | $364.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $24.00K 10-Q · filed 2025-05-13 | $147.00K derived: sum of 2 quarters · filed 2025-05-13 | $379.00K derived: sum of 3 quarters · filed 2025-05-13 | $598.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $355.00K derived: sum of 2 quarters · filed 2025-03-18 | $574.00K derived: sum of 3 quarters · filed 2025-03-18 | $1.15M 10-K · filed 2025-03-18 |
| 2023-09-30 | $232.00K 10-Q · filed 2024-11-05 | $451.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.03M 10-Q · filed 2024-11-05 | $1.56M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $219.00K 10-Q · filed 2024-08-07 | $796.00K 10-Q · filed 2024-08-07 | $1.32M derived: sum of 3 quarters · filed 2024-08-07 | $897.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $577.00K 10-Q · filed 2024-05-06 | $1.10M derived: sum of 2 quarters · filed 2024-05-06 | $678.00K derived: sum of 3 quarters · filed 2024-05-06 | $86.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $101.00K derived: sum of 2 quarters · filed 2024-03-25 | -$491.00K derived: sum of 3 quarters · filed 2024-03-25 | -$1.01M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$427.00K 10-Q · filed 2023-11-07 | -$1.02M derived: sum of 2 quarters · filed 2023-11-07 | -$1.53M 10-Q · filed 2023-11-07 | -$1.68M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$592.00K 10-Q · filed 2023-08-07 | -$1.11M 10-Q · filed 2023-08-07 | -$1.25M derived: sum of 3 quarters · filed 2023-08-07 | -$1.23M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$516.00K 10-Q · filed 2023-05-04 | -$662.00K derived: sum of 2 quarters · filed 2023-05-04 | -$642.00K derived: sum of 3 quarters · filed 2023-05-04 | -$684.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$126.00K derived: sum of 2 quarters · filed 2023-03-06 | -$168.00K derived: sum of 3 quarters · filed 2023-03-06 | -$168.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $20.00K 10-Q · filed 2022-11-14 | -$22.00K derived: sum of 2 quarters · filed 2022-11-14 | -$22.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$42.00K 10-Q · filed 2022-08-08 | -$42.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |